Search results
Results from the WOW.Com Content Network
While Malone promotes himself as the inventor of mRNA vaccines, [1] [7] credit for the distinction is more often given to the lead authors on the major papers he contributed to (such as Felgner and Wolff), later advances by Katalin Karikó and Drew Weissman, [3] [19] or Moderna co-founder Derrick Rossi. [13]
An mRNA vaccine is a type of vaccine that uses a copy of a molecule called messenger RNA (mRNA) to produce an immune response. [1] The vaccine delivers molecules of antigen -encoding mRNA into cells , which use the designed mRNA as a blueprint to build foreign protein that would normally be produced by a pathogen (such as a virus ) or by a ...
Drew Weissman (born September 7, 1959) is an American physician and immunologist known for his contributions to RNA biology. Weissman is the inaugural Roberts Family Professor in Vaccine Research, director of the Penn Institute for RNA Innovation, and professor of medicine at the Perelman School of Medicine at the University of Pennsylvania (Penn).
This technology has been licensed by BioNTech and Moderna to develop their protein replacement technologies, but it was also used for their COVID-19 vaccines. [20] The messenger RNA-based technology developed by Karikó and the two most effective vaccines based on it, BioNTech/Pfizer and Moderna, have formed the basis for the effective and ...
Hoerr did experimental research on the stabilization of messenger ribonucleic acid (mRNA). In 1999, he received his PhD from Günther Jung, Institute of Organic Chemistry, in cooperation with Hans-Georg Rammensee, Institute of Immunology and Cell Biology (both: University of Tübingen) on the topic of RNA vaccines for the induction of specific cytotoxic T lymphocytes (CTL) and antibodies.
Risk of heart inflammation from mRNA vaccines is being studied, creator says.
A vaccine for pancreatic cancer could ... an experimental approach to treating the cancer with a messenger RNA (mRNA)-based therapeutic vaccine "continues to show potential" in reducing the risk ...
The international TPP team was formed to 1) assess the development of the most promising candidate vaccines; 2) map candidate vaccines and their clinical trial worldwide, publishing a frequently-updated "landscape" of vaccines in development; [78] 3) rapidly evaluate and screen for the most promising candidate vaccines simultaneously before ...